RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00033101.xml
![](/products/assets/desktop/img/oa-logo.png)
CC BY-NC-ND 4.0 · Neurology International Open 2018; 02(01): E56-E59
DOI: 10.1055/s-0043-125342
DOI: 10.1055/s-0043-125342
Review
Escalation Strategies in the Treatment of Refractory Myasthenia Gravis
Weitere Informationen
Publikationsverlauf
Publikationsdatum:
21. Februar 2018 (online)
![](https://www.thieme-connect.de/media/10.1055-s-00033101/201801/lookinside/thumbnails/181_10-1055-s-0043-125342-1.jpg)
Abstract
Among all patients with myasthenia gravis (MG), 10 to 15% are considered to be refractory to (expanded) standard treatments. Current international consensus guidelines for the management of myasthenia gravis recommend referral of refractory MG patients to centers with expertise in the treatment of MG and chronic intravenous immunoglobulin therapy or plasmapheresis. Here we briefly summarize current approaches to overcome refractory myasthenia gravis.
-
References
- 1 Sanders DB, Wolfe GI, Benatar M. et al. International consensus guidance for management of myasthenia gravis: Executive summary. Neurology 2016; 87: 419-425
- 2 Tandan R, Hehir 2nd MK, Waheed W. et al. Rituximab treatment of myasthenia gravis: A systematic review. Muscle Nerve 2017; 56: 185-196
- 3 Anderson D, Phan C, Johnston WS. et al. Rituximab in refractory myasthenia gravis: A prospective, open-label study with long-term follow-up. Ann Clin Transl Neurol 2016; 3: 552-555
- 4 Iorio R, Damato V, Alboini PE. et al. Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis. J Neurol 2015; 262: 1115-1119
- 5 Robeson KR, Kumar A, Keung B. et al. Durability of the rituximab response in acetylcholine receptor autoantibody-positive myasthenia gravis. JAMA Neurol 2017; 74: 60-66
- 6 Lebrun C, Bourg V, Bresch S. et al. Therapeutic target of memory B cells depletion helps to tailor administration frequency of rituximab in myasthenia gravis. J Neuroimmunol 2016; 298: 79-81
- 7 Afanasiev V, Demeret S, Bolgert F. et al. Resistant myasthenia gravis and rituximab: A monocentric retrospective study of 28 patients. Neuromuscul Disord 2017; 27: 251-258
- 8 Kanth KM, Solorzano GE, Goldman MD. PML in a patient with myasthenia gravis treated with multiple immunosuppressing agents. Neurol Clin Pract 2016; 6: e17-e19
- 9 Braune SA, Wichmann D, von Heinz MC. et al. Clinical features of critically ill patients with Shiga toxin-induced hemolytic uremic syndrome. Crit Care Med 2013; 41: 1702-1710
- 10 Howard Jr. JF, Barohn RJ, Cutter GR. et al. A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis. Muscle Nerve 2013; 48: 76-84
- 11 Howard Jr. JF, Utsugisawa K, Benatar M. et al. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): A phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol 2017; 16: 976-986
- 12 Ärztlicher Beirat der Deutschen Myasthenie Gesellschaft (DMG). Ärztlicher Beirat zu Eculizumab-Therapie [online]. Available at: http://www.dmg-online.de/aerztlicher-beirat-zu-eculizumab-therapie/Accessed 18.12.2017
- 13 De Feo LG, Schottlender J, Martelli NA. et al. Use of intravenous pulsed cyclophosphamide in severe, generalized myasthenia gravis. Muscle Nerve 2002; 26: 31-36
- 14 Drachman DB, Adams RN, Hu R. et al. Rebooting the immune system with high-dose cyclophosphamide for treatment of refractory myasthenia gravis. Ann N Y Acad Sci 2008; 1132: 305-314
- 15 Gladstone DE, Brannagan 3rd TH, Schwartzman RJ. et al. High dose cyclophosphamide for severe refractory myasthenia gravis. J Neurol Neurosurg Psychiatry 2004; 75: 789-791
- 16 Buzzard KA, Meyer NJ, Hardy TA. et al. Induction intravenous cyclophosphamide followed by maintenance oral immunosuppression in refractory myasthenia gravis. Muscle Nerve 2015; 52: 204-210
- 17 Nagappa M, Netravathi M, Taly AB. et al. Long-term efficacy and limitations of cyclophosphamide in myasthenia gravis. J Clin Neurosci 2014; 21: 1909-1914
- 18 Bryant A, Atkins H, Pringle CE. et al. Myasthenia gravis treated with autologous hematopoietic stem cell transplantation. JAMA Neurol 2016; 73: 652-658
- 19 Smith CI, Hammarstrom L, Lefvert AK. Bone-marrow grafting induces acetylcholine receptor antibody formation. Lancet 1985; 1: 978
- 20 Tsutsumi Y, Kamiishi T, Kikuchi R. et al. Myasthenia gravis after allogeneic bone marrow transplantation: A case report and literature review. Hematol Oncol Stem Cell Ther 2017; DOI: 10.1016/j.hemonc.2017.04.001.